.Pharmacolibrary.Drugs.ATC.D.D11AH11 .Pharmacolibrary.Drugs.ATC.D.D11AH11| name: | Delgocitinib |
| ATC code: | D11AH11 | route: | topical |
| n-compartments | 1 |
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor indicated for the treatment of atopic dermatitis. It inhibits JAK1, JAK2, JAK3, and TYK2 and is approved as a topical ointment in some countries including Japan and the EU. Delgocitinib modulates immune response and inflammation associated with dermatological conditions.
No published human pharmacokinetic model parameters are available for topical delgocitinib. Limited data indicates minimal systemic absorption following topical administration in adults with atopic dermatitis.
Nakagawa, H, et al., & Ninomiya, N (2018). Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. The Journal of dermatology 45(6) 701–709. DOI:10.1111/1346-8138.14322 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29665062